Table 2.
Examples of clinical studies for viral vector-based SARS-CoV-2 vaccine candidates.
| Vector | Phase | Response | Ref |
|---|---|---|---|
| Ad5-SARS-CoV-2-S | I | SARS-CoV-2-specific cellular and humoral responses | [59] |
| Ad5-SARS-CoV-2-S | II | Strong neutralizing SARS-CoV-2-specific antibodies | [60] |
| Ad5-SARS-CoV-2-S | III | Recruitment in progress | [61] |
| Ad5-SARS-CoV-2-S | III | Study in progress | [62] |
| Ad26.COV2 S | I/II | Good safety, strong immunogenicity | [63,64] |
| Ad26.COV2 S | III | Recruitment in progress | [65] |
| Ad26.COV2 S | III | Recruitment in progress | [66] |
| rAd26-S/rAd5-S | I/II | Good safety, strong immune responses | [42] |
| rAd26-S/rAd5-S | III | Recruitment in progress | [67] |
| rAd26-S/rAd5-S | III | Study in progress | [68] |
| rAd26-S/rAd5-S | III | Study planned | [69] |
| rAd26-S/rAd5-S | III | 91.6% vaccine efficacy from interim results | [70] |
| ChAdOx1 nCOV-19 | I/II | Humoral and cellular immune responses | [72] |
| ChAdOx1 nCOV-19 | II/III | Similar nAb responses in all age groups | [74] |
| ChAdOx1 nCoV-19 | III | Recruitment in progress | [75] |
| ChAdOx1 nCoV-19 | III | Recruitment in progress | [76] |
| ChAdOx1 nCoV-19 | III | Study in progress | [77] |
| ChAdOx1 nCoV-19 | III | Study in progress | [78] |
| ChAdOx1 nCoV-19 | III | Interim results: 62.1–90.0% efficacy in 4 trials | [80] |
| MVA-SARS-COV-2 | I | Recruitment in progress | [81] |
| MVA-SARS-COV-2 | I | Recruitment in progress | [82] |
| LV-DC + CTL Ag | I | Recruitment in progress | [83] |
| MV-SASR-CoV-2-S | I | Trial discontinued | [84] |
| VSV | I | Trial discontinued | [85] |
| VSV | I/II | Recruitment in progress | [86] |
| IFV-CoV-2 S RBD | I | Registered trial | [87] |
| IFV-CoV-2 S RBD | II | Registered trial | [88] |
Ad, adenovirus; Ag, antigen; ChAdOx1-S, simian adenovirus expressing SARS-CoV-2 S protein; CTLs, cytotoxic T lymphocytes; IFV, Influenza virus; LV-DCs, lentivirus-transduced dendritic cells; MV, measles virus; MVA, modified vaccinia virus Ankara; nAb, neutralizing antibody; RBD, receptor binding domain; VSV, vesicular stomatitis virus.